Munich Reinsurance Co Stock Corp in Munich acquired a new position in IQVIA Holdings Inc. (NYSE:IQV – Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 5,279 shares of the medical research company’s stock, valued at approximately $1,020,000.
Several other institutional investors have also added to or reduced their stakes in IQV. Ascentis Independent Advisors purchased a new position in shares of IQVIA in the first quarter worth about $25,000. Financial Freedom LLC bought a new position in IQVIA in the 1st quarter worth approximately $25,000. International Assets Investment Management LLC purchased a new position in IQVIA in the 4th quarter valued at approximately $27,000. Gilpin Wealth Management LLC bought a new stake in IQVIA during the 4th quarter valued at $27,000. Finally, Compass Financial Management LLC purchased a new stake in shares of IQVIA during the second quarter worth $27,000. 89.62% of the stock is owned by hedge funds and other institutional investors.
Insider Activity
In other IQVIA news, insider Eric Sherbet sold 5,000 shares of the firm’s stock in a transaction dated Wednesday, July 29th. The stock was sold at an average price of $249.16, for a total transaction of $1,245,800.00. Following the sale, the insider owned 20,999 shares in the company, valued at $5,232,110.84. This trade represents a 19.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Bhavik Patel sold 1,855 shares of the company’s stock in a transaction dated Friday, July 31st. The stock was sold at an average price of $235.27, for a total value of $436,425.85. Following the completion of the transaction, the insider owned 1,348 shares of the company’s stock, valued at $317,143.96. The trade was a 57.91% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 15,581 shares of company stock worth $3,796,021. Corporate insiders own 1.70% of the company’s stock.
IQVIA Stock Down 1.6%
IQVIA (NYSE:IQV – Get Free Report) last announced its earnings results on Tuesday, July 28th. The medical research company reported $3.15 earnings per share for the quarter, beating analysts’ consensus estimates of $3.03 by $0.12. IQVIA had a net margin of 8.10% and a return on equity of 30.25%. The business had revenue of $4.37 billion for the quarter, compared to the consensus estimate of $4.30 billion. During the same period last year, the firm posted $2.81 earnings per share. IQVIA’s quarterly revenue was up 8.7% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. Sell-side analysts expect that IQVIA Holdings Inc. will post 11.57 earnings per share for the current fiscal year.
Analyst Ratings Changes
Several equities analysts have recently weighed in on IQV shares. Stifel Nicolaus lifted their price target on IQVIA from $220.00 to $276.00 and gave the company a “buy” rating in a research report on Wednesday, July 29th. TD Cowen raised their target price on IQVIA from $233.00 to $288.00 and gave the stock a “buy” rating in a research note on Wednesday, July 29th. Robert W. Baird increased their price target on shares of IQVIA from $252.00 to $287.00 and gave the stock an “outperform” rating in a report on Wednesday, July 29th. Mizuho boosted their price objective on shares of IQVIA from $215.00 to $230.00 and gave the company an “outperform” rating in a research note on Monday, July 13th. Finally, Deutsche Bank Aktiengesellschaft set a $240.00 target price on shares of IQVIA in a report on Thursday, July 9th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $243.62.
Get Our Latest Research Report on IQV
IQVIA Profile
IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.
IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.
Read More
- Five stocks we like better than IQVIA
- Revolution Medicines Got Its Breakthrough—What Moves It Next?
- Retail Earnings Just Exposed a Bigger Divide in the U.S. Consumer Economy
- FB Financial’s Southern Expansion and Buybacks Drive Analyst Optimism
- AST SpaceMobile Stock Soared 12%—This Was the Catalyst
Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IQVIA Holdings Inc. (NYSE:IQV – Free Report).
Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.
